Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Epstein

Showing results (361-370 of 374) with videos related to

Pageof 38
Sort By:
Haematologica|June 11, 2026
Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patternsRobert Stuver, Zachary R Moore, Stefan K Barta, et al.
Circulation|October 7, 2004
Left ventricular form and function: scientific priorities and strategic planning for development of new views of diseaseGerald D Buckberg, Myron L Weisfeldt, Manel Ballester, et al.
Haematologica|August 30, 2023
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluationZachary D Epstein-Peterson, Esther Drill, Umut Aypar, et al.
Haematologica|August 1, 2024
<i>Erratum</i> to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluationZachary D Epstein-Peterson, Esther Drill, Umut Aypar, et al.
Haematologica|May 16, 2024
Emapalumab as salvage therapy for adults with malignancy-associated hemophagocytic lymphohistiocytosisWilliam T Johnson, Zachary D Epstein-Peterson, Nivetha Ganesan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2026
Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in <i>TP53</i>-Mutated Diffuse Large B-Cell LymphomaManik Uppal, Bhavneet Bhinder, Andrew R Marderstein, et al.
Haematologica|December 8, 2018
Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemiaWenbin Xiao, Aaron D Goldberg, Christopher A Famulare, et al.
Blood Advances|May 4, 2023
Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemiaJoseph G W McCarter, David Nemirovsky, Christopher A Famulare, et al.
Blood Advances|June 12, 2023
Retrospective characterization of nodal marginal zone lymphomaRobert Stuver, Esther Drill, David Qualls, et al.
Blood Advances|April 20, 2023
TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapyWilliam T Johnson, Nivetha Ganesan, Zachary D Epstein-Peterson, et al.
Pageof 38

Showing results (361-370 of 374) with videos related to

Sort By:
Pageof 38
Haematologica|June 11, 2026
Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patternsRobert Stuver, Zachary R Moore, Stefan K Barta, et al.
Circulation|October 7, 2004
Left ventricular form and function: scientific priorities and strategic planning for development of new views of diseaseGerald D Buckberg, Myron L Weisfeldt, Manel Ballester, et al.
Haematologica|August 30, 2023
Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluationZachary D Epstein-Peterson, Esther Drill, Umut Aypar, et al.
Haematologica|August 1, 2024
<i>Erratum</i> to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluationZachary D Epstein-Peterson, Esther Drill, Umut Aypar, et al.
Haematologica|May 16, 2024
Emapalumab as salvage therapy for adults with malignancy-associated hemophagocytic lymphohistiocytosisWilliam T Johnson, Zachary D Epstein-Peterson, Nivetha Ganesan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 2026
Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in <i>TP53</i>-Mutated Diffuse Large B-Cell LymphomaManik Uppal, Bhavneet Bhinder, Andrew R Marderstein, et al.
Haematologica|December 8, 2018
Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemiaWenbin Xiao, Aaron D Goldberg, Christopher A Famulare, et al.
Blood Advances|May 4, 2023
Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemiaJoseph G W McCarter, David Nemirovsky, Christopher A Famulare, et al.
Blood Advances|June 12, 2023
Retrospective characterization of nodal marginal zone lymphomaRobert Stuver, Esther Drill, David Qualls, et al.
Blood Advances|April 20, 2023
TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapyWilliam T Johnson, Nivetha Ganesan, Zachary D Epstein-Peterson, et al.
Pageof 38